Progression of motor deficits in glioma-bearing mice: impact of CNF1 therapy at symptomatic stages.

ABSTRACT: Glioblastoma (GBM) is the most aggressive type of brain tumor. In this context, animal models represent excellent tools for the early detection and longitudinal mapping of neuronal dysfunction, that are critical in the preclinical validation of new therapeutic strategies. In a mouse glioma model, we developed sensitive behavioral readouts that allow early recognizing and following neurological symptoms. We injected GL261 cells into the primary motor cortex of syngenic mice and we used a battery of behavioral tests to longitudinally monitor the dysfunction induced by tumor growth. Grip strength test revealed an early onset of functional deficit associated to the glioma growth, with a significant forelimb weakness appearing 9 days after tumor inoculation. A later deficit was observed in the

SUBMITTER: Vannini E 

PROVIDER: S-EPMC5410325 | biostudies-literature | 2017 Apr

REPOSITORIES: biostudies-literature